Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Departments of Genomic Medicine and Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Leuk Lymphoma. 2022 Jan;63(1):19-30. doi: 10.1080/10428194.2021.1975192. Epub 2021 Sep 6.
Plasmacytoid dendritic cells (pDCs) serve as immunoregulatory antigen-presenting cells that play a role in various inflammatory, viral, and malignant conditions. Malignant proliferation of pDCs is implicated in the pathogenesis of certain hematologic cancers, specifically blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myelogenous leukemia with clonal expansion of pDC (pDC-AML). In recent years, BPDCN and pDC-AML have been successfully treated with targeted therapy of pDC-specific surface marker, CD123. However, relapsed and refractory BPDCN remains an elusive cancer, with limited therapeutic options. CD303 is another specific surface marker of human pDCs, centrally involved in antigen presentation and immune tolerance. Monoclonal antibodies directed against CD303 have been studied in preclinical models and have achieved disease control in patients with cutaneous lupus erythematosus. We performed a comprehensive review of benign and malignant disorders in which CD303 have been studied, as there may be a potential future CD303-directed therapy for many of these conditions.
浆细胞样树突状细胞 (pDCs) 作为免疫调节性抗原呈递细胞，在各种炎症、病毒和恶性疾病中发挥作用。pDC 的恶性增殖与某些血液系统癌症的发病机制有关，特别是原始浆细胞样树突状细胞瘤 (BPDCN) 和伴有 pDC 克隆性扩增的急性髓系白血病 (pDC-AML)。近年来，针对 pDC 特异性表面标志物 CD123 的靶向治疗已成功用于治疗 BPDCN 和 pDC-AML。然而，复发和难治性 BPDCN 仍然是一种难以捉摸的癌症，治疗选择有限。CD303 是另一种人 pDC 的特异性表面标志物，在抗原呈递和免疫耐受中起核心作用。针对 CD303 的单克隆抗体已在临床前模型中进行了研究，并在患有皮肤红斑狼疮的患者中实现了疾病控制。我们对 CD303 已被研究的良性和恶性疾病进行了全面回顾，因为针对 CD303 的未来治疗可能会对这些疾病中的许多疾病有效。
